SCHEMBL30983420

SCHEMBL30983420

CC1(Oc2ncnc3c2nc(-c2ccc(OCCCN4CCNCC4)cc2Cl)n3Cc2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 5/20 0.41
▸ PDE2A O00408 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.39
▸ DRD2 P14416 2/20 0.37
▸ ADRA1A P35348 2/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ LTA4H P09960 1/20 0.36
▸ PRKAB2 O43741 1/20 0.36
▸ PRKAG1 P54619 1/20 0.36
▸ PRKAA2 P54646 1/20 0.36
▸ PRKAA1 Q13131 1/20 0.36
▸ PRKAG3 Q9UGI9 1/20 0.36
▸ PRKAG2 Q9UGJ0 1/20 0.36
▸ PRKAB1 Q9Y478 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ AVPR1B P47901 1/20 0.36
▸ PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983795 0.96 PDE2A (0.42) HRH4PDE2ATLR7DRD2LTA4H
SCHEMBL30984056 0.93 PDE2A (0.42) HRH4PDE2ADRD2ADRA1AKCNH2
SCHEMBL30984054 0.93 PDE2A (0.42) HRH4PDE2ADRD2ADRA1AKCNH2
SCHEMBL30983566 0.92 THRB (0.41) HRH4TLR7ADRA1AKCNH2HRH3
SCHEMBL30983378 0.91 HTR6 (0.41) HRH4PDE2ATLR7DRD2KCNH2
SCHEMBL30983531 0.91 PDE2A (0.43) HRH4PDE2ADRD2LTA4HPRKAB2
SCHEMBL30983470 0.89 GRM2 (0.35) HRH4TLR7ADRA1AKCNH2HRH3
SCHEMBL30983822 0.89 DRD2 (0.42) HRH4TLR7DRD2LTA4HPIK3CD
SCHEMBL30983522 0.88 PDE2A (0.41) HRH4PDE2ADRD2LTA4HALDH1A1
SCHEMBL30983471 0.88 PIK3CD (0.39) HRH4TLR7DRD2ADRA1AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HRH4 4696/4885PDE2A 1118/4885TLR7 4408/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HRH4 4696/4885PDE2A 1118/4885TLR7 4408/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HRH4 4696/4885PDE2A 1118/4885TLR7 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback